Integer (ITGR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual meeting scheduled for May 20, 2026, at the Hilton Dallas/Plano Granite Park Hotel at 9:00 a.m. Central Time.
Proxy materials are available online, and shareholders are encouraged to review them before voting.
Voting can be done electronically until 11:59 p.m. Eastern Time on May 19, 2026.
Voting matters and shareholder proposals
Election of 11 directors for a one-year term or until successors are elected and qualified.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
Advisory non-binding vote to approve named executive officer compensation.
Approval of the 2026 Omnibus Incentive Plan.
Consideration of other matters that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and all proposals listed.
List of 11 director nominees provided, including Sheila Antrum, Cheryl C. Capps, and others.
Latest events from Integer
- 2025 saw 8% sales and 21% EPS growth; 2026 guidance is stable with strong long-term prospects.ITGR
Q4 20259 Apr 2026 - Annual meeting to vote on directors, auditor, executive pay, and new incentive plan amid strong 2025 results.ITGR
Proxy filing6 Apr 2026 - Temporary product headwinds in 2026 are expected to give way to above-market growth in 2027.ITGR
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Above-market growth is expected in 2027, driven by a robust pipeline and new product launches.ITGR
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2026 outlook projects flat to modest sales growth, strong pipeline, and continued capital discipline.ITGR
47th Annual Raymond James Institutional Investor Conference6 Mar 2026 - Temporary 2026 headwinds expected to give way to above-market growth in 2027 via new launches.ITGR
Citi Annual Global Healthcare Conference 20253 Feb 2026 - Targeting above-market growth and margin expansion through innovation, integration, and M&A.ITGR
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 sales up 9%, profit outlook raised, and Medical segment growth drove margin gains.ITGR
Q2 20242 Feb 2026 - Raised 2024 guidance, accelerating growth in high-value medtech markets, and strong margin expansion.ITGR
2024 Wells Fargo Healthcare Conference22 Jan 2026